Lower Limbs Articles & Analysis
-
We continue testing HANK
In collaboration with CEIT, we have been carrying out different trials with our lower limb exoskeleton under the Eurobench project. The tests have been carried out in different environments such as: ramps, stairs, etc. The results have been very favourable, confirming the versatility of our lower limb exoskeleton. In addition, the test results will contribute to the improvement of walking ...
-
ISPRM 2022 is now over - Lisbon PT
ISPRM 2022 is now over | International Society of Physical and Rehabilitation Medicine | Lisbon PT After 4 nice days and some smart presentations, ISPRM 2022 now ends with great memories. New device presentation: IVS4 for Lower Limbs as a complementary approach to balance exercise, strengthening and robotic rehabilitation for gait recovery Lecture: Comparison of EEG biomarkers in Mirror ...
-
Effects of prosthetic limb prescription on 3-year mortality among Veterans with lower-limb amputation
Method: Retrospective observational study on 4,578 Veterans hospitalized for LLA and discharged 2003- 2004, looking at time to all-cause mortality from the amputation surgical date up to the 3 yr anniversary. Results: 1,300 (28.4%) persons received a prescription for a prosthetic limb within 1 yr after the surgical amputation. About 46% (n = 2,086) of all Veterans w LLA died within 3 yr of the ...
-
IVS3 is now a must-have device in France
French hospitals and clinics invest significantly on new technologies to improve their patient care services. Our IVS3 device plays a key role in the rehabilitation pathway, especially in neurologic field. This is a large success for our innovation in less than 4 years. IVS3 is a unique technology dedicated to motor planning and central control of movement. It is used in various specialties: ...
-
Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius High Frequency Nerve Block System
Neuros Medical, Inc., announced today that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel High-Frequency Nerve Block system as an aid in the management of chronic intractable pain of the lower limb of adult amputees. The FDA Breakthrough Device Program is intended to help patients and health care providers receive timely ...
-
DIH-HERO project “EngageABLE”
We are pleased to announce that “EngageABLE”, a project of ABLE Human Motion in collaboration with the dutch hospital Sint Maartenskliniek, has been awarded for funding by DIH-HERO. The goal of this project is to enhance the capabilities of the ABLE Exoskeleton to promote users’ motivation and faster learning. DIH-HERO is an independent platform that connects Digital Innovation ...
-
Aurealis Therapeutics Publishes First Study on Four-in-One-Combination Therapy Using Live Lactococcus Lactis Expressing Three Human Therapeutic Proteins for the Treatment of Chronic Non-Healing Wounds
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This announcement comes as the ...
-
Soundbite Medical Solutions Receives FDA 510(k) Clearance for the SoundBite® Crossing System – Peripheral (14P)
Soundbite announces the company has received Food and Drug Administration (FDA) 510(k) clearance for the SoundBite® Crossing System - Peripheral (SCS-P) with the 0.014” Active Wire (14P). The SoundBite Crossing System – Peripheral (14P) is a recanalization tool, designed to help physician’s placement of conventional guidewires or treatment devices in the intraluminal space ...
-
Soundbite Medical’s Proprietary Shock Wave Technology Now Cracks Calcium In Germany, a Promising Solution for CLI Patients
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific peripheral and coronary arterial diseases, today announced the use of its novel Active Wire 0.014” platform at a prominent site in Germany with the successful treatment of patients suffering from heavily calcified lower limb chronic total ...
-
FDA Awards Breakthrough Device Designation to the ReWalk ReBoot Soft Exo-Suit
ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a leading global manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced its ReBoot device has been granted designation as a Breakthrough Device by the Food and Drug Administration (FDA). The ReBoot is a lightweight, battery-powered orthotic exo-suit intended to assist ambulatory ...
-
ReWalk Robotics Appoints Senior Biotech Executive, Jeannine Lynch, as Vice President of Strategy and Market Access
ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced Jeannine Lynch will join the Company on August 31, 2021, as Vice President of Strategy and Market Access. Ms. Lynch will focus on completing the building and implementation of ReWalk’s market access ...
-
Soundbite Medical Solutions Announces Issuance of a Third U.S. Patent Expanding Coverage of its Core Technology
Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific peripheral and coronary arterial diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,000,880, entitled “Mechanical Waveguide Provided With A Marker Thereon”. The patent is directed ...
-
National Institute for Health and Care Excellence (NICE) Publishes Briefing on ReStore Soft Exo-Suit in the UK
ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the "Company"), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced its ReStore Soft Exo-Suit was the subject of a recent Medtech Innovation Briefing (MIB) by the UK's National Institute for Health and Care Excellence (NICE). These briefings are designed to support National Health Services (NHS) ...
-
Study: Pathbreaking Technology Completely Eliminated Major Diabetic Amputations
Research conducted by Kaiser Permanente also found once-daily remote temperature monitoring with Podimetrics decreased overall resource utilization SOMERVILLE, Mass., October 14, 2020 — Podimetrics, a virtual care management company with the leading solution to help prevent costly and deadly diabetic amputations, today announced results from its latest study of patients at high risk of ...
-
Research Finds Nearly 40% of Diabetes Patients who Suffer a Lower Extremity Amputation Endure Another Within Five Years
Reamputation Rates Have Not Improved Over Two Decades. SOMERVILLE, Mass., June 10, 2021 — Podimetrics, a virtual care management company dedicated to preventing costly and deadly diabetic amputations, today announced results from its latest research, which found patients with diabetes who have an amputation have a 37 percent chance of having reamputation within five years. The ...
-
Research Presented at LINC Suggests the Profusa Lumee® Oxygen Platform May Improve Clinical Management of Patients with Critical Limb Ischemia
Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced research findings that suggest the company’s Lumee® Oxygen Platform may help improve the clinical management of patients with critical limb ischemia (CLI) who are undergoing endovascular revascularization treatment (EVT). The data, from a recent post-market clinical study ...
-
On the road to IPO, Field Orthopaedics raises $5m for push into US
The rapidly growing Australian orthopaedics devices company, Field Orthopaedics (FO) has just completed a fresh round of fundraising, equipping it with $5million in new capital for a push into the US$11billion trauma and extremities market. As one of the fastest growing market sub-sectors, at a rate of 7-10% per annum, hand and wrist orthopaedics is now around 40% of the upper extremities market. ...
-
Villa Beretta Rehabilitation Center - BioXtreme Post Marketing Evaluation Site
Villa Beretta Rehabilitation Center and BioXtreme are proud to announce that they have agreed to conduct a joint evaluation project in the hospital’s facility in Costa-Masnaga, Italy. BioXtreme has developed a ground-breaking robotic device for motor-learning, based on innovative error enhancement technology for upper limb rehabilitation from stroke and other neurological injuries. Villa ...
-
Research Finds All-Cause Hospitalizations are Nearly Three Times More Likely During a Diabetic Foot Ulcer Episode
SOMERVILLE, Mass., January 18, 2022 — Podimetrics, a virtual care support company dedicated to preventing costly and deadly diabetic amputations, today announced results from its latest research, which compared the health of individuals during and after periods of diabetic foot ulceration — open sores or wounds on the foot, which commonly occur among those with diabetes and are the ...
-
Profusa Receives CE Mark Approval to Market the Wireless Lumee® Oxygen Platform for Continuous, Real-Time Monitoring of Tissue Oxygen
Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced it has received Conformité Européenne (CE) Mark approval to market its Wireless Lumee® Oxygen Platform for continuous, real-time monitoring of tissue oxygen in patients with potential acute and/or chronic changes in tissue oxygen levels who may benefit from ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you